← Back to Search

Cleaning and Disinfecting Solution

BL-3100-NBR03 for Refractive Errors

N/A
Waitlist Available
Research Sponsored by Bausch & Lomb Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
No Placebo-Only Group

Summary

This trial involves 340 participants who will wear special contact lenses daily for a period of time. The lenses will be replaced regularly to test their effectiveness and safety.

Eligible Conditions
  • Refractive Errors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall comfort averaged over all scheduled follow-up visits
Dental Deposits
The proportion of eyes with any slit-lamp findings greater than Grade 2 over all follow-up visits.
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: BL-3100-NBR03Experimental Treatment1 Intervention
BL-3100-NBR03 multi-purpose solution
Group II: renu® Advanced FormulaActive Control1 Intervention
renu® Advanced Formula multi-purpose solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BL-3100-NBR03 multi-purpose solution
2023
N/A
~300

Find a Location

Who is running the clinical trial?

Bausch & Lomb IncorporatedLead Sponsor
257 Previous Clinical Trials
57,934 Total Patients Enrolled
6 Trials studying Refractive Errors
603 Patients Enrolled for Refractive Errors
Daniel DonatelloStudy DirectorBausch & Lomb Incorporated
4 Previous Clinical Trials
1,672 Total Patients Enrolled
~118 spots leftby Nov 2025